EMA: Renewal of Q&A Document for "Centralized Procedures"
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
In February 2025, the "Questions & Answers (Q&A)" document relating to centralized procedures was updated and published on the website of the European Medicines Agency (EMA).
The new version of the Q&A document "European Medicines Agency post-authorisation procedural advice for users of the centralised procedure", which addresses issues that may be relevant after marketing authorisation has been granted, contains some additions and revisions in the following passages:
Chapter 1 Type IA Variations
There have been updates to the following questions:
- 1.4. How shall I present and submit my Type IA/ IAIN Variation(s)?
- 1.12. When do I have to submit revised product information? In all languages?
Chapter 2 Type IB variations
The following questions have been adapted in this chapter:
- 2.4. How shall I present and submit my Type IB Variation?
- 2.5. When shall I submit my Type IB Variation?
- 2.10. How should I submit revised product information? In all languages?
In the answer to question 2.4., the paragraph "Variations to implement changes for generic/hybrid/biosimilar products" was added.
Chapter 3 Type II variations
In chapter 3, the answer to one question has been revised:
- 3.16. When do I have to submit revised product information? In all languages?
Chapter 6 Worksharing of variations
There were updates in the following question:
- 6.10. When do I have to submit revised product information? In all languages?
Chapter 19 Transfer of Marketing Authorisation
In chapter 19, the answer to the following question has been revised:
- 19.2. How shall I present my application for the Transfer of Marketing Authorisation?
Chapter 22 Article 61(3) Notifications
The following question has been adapted in this chapter:
- 22.4. How shall I present my 61(3) Notification?
The latest version of the "Q&A" document for central procedures "European Medicines Agency post-authorisation procedural
advice for users of the centralised procedure" can be found here.
Related GMP News
21.10.2026EMA Clarifies ESMP Reporting for Critical Medicine Shortages
20.10.2026EDQM Updates Guidance on CEP Sister File Applications
20.10.2026EDQM Revises Guidance on Electronic Submissions for CEP Applications
14.10.2026Bioassays in the United States Pharmacopoeia - Two Chapters come into Force in Spring
07.10.2026CEP 2.0: EDQM Updates Guidance on the Use of Certificates of Suitability
23.09.2026IRIS Portal: EMA expands digital Procedure Management